The Pershing Square Sohn Cancer Research Alliance has announced the winners of the 2016 Pershing Square Sohn Prize for Young Investigators in Cancer Research. The annual prize aims to catalyze collaboration among young investigators, academics, nonprofits, investors, and the biotech and pharmaceutical industries. The prize-winners will each receive funding for up to three years. Two of the seven awards were granted to Damon Runyon scientists:  

Election to the National Academy of Sciences is one of the highest honors that can be earned by a U.S. scientist. In recognition of their distinguished and continuing achievements in original biomedical research, members of the Damon Runyon community of scientists were inducted this May:

DAMON RUNYON FELLOWS

Adrian P. Bird, PhD (Damon Runyon Fellow '71-'73), Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, United Kingdom 

Cameron J. Turtle, MD, PhD (Damon Runyon Clinical Investigator ’13-’16) and colleagues at the Fred Hutchinson Cancer Research Center, Seattle, successfully refined a cancer immunotherapy treatment, resulting in no detectable disease in 27 of 29 adult patients (93%) with B-cell acute lymphoblastic leukemia, or ALL. The pioneering technique uses two subsets of genetically engineered immune T-cells from the patient (CD19 CAR-T cells) to target and attack the cancer.

Azad Bonni, MD, PhD (Damon Runyon Fellow ’96-’97) of Washington University School of Medicine, St. Louis, and colleagues, were the first to show that a protein called OSMR (Oncostatin M Receptor) is required for glioblastoma tumors to form. They found that blocking OSMR activity in brain tumor stem cells prevented them from forming tumors in mouse brains. In addition, an analysis of 339 tumor samples from human glioblastoma patients showed that higher OSMR expression corresponded with worse patient survival outcome.

The American Association for Cancer Research (AACR) named several Damon Runyon scientists as 2016 recipients of its prestigious awards.

AACR Princess Takamatsu Memorial Lectureship: William G. Kaelin, Jr., MD (Damon Runyon Board Member, Chair of Clinical Investigator Award Committee), Dana-Farber Cancer Institute, Boston

AACR-CRI Lloyd J. Old Award in Cancer Immunology: Ronald Levy, MD (Damon Runyon Board Member, Innovation Award Committee Member), Stanford University, Stanford

Ash Alizadeh, MD, PhD (Damon Runyon Clinical Investigator ’14-’17) and colleagues at Stanford University School of Medicine, Stanford, developed an enhanced technique that significantly increases the ability to accurately identify and sequence DNA from cancer cells circulating in a person’s blood. The technique, called “iDES-enhanced CAPP-Seq,” can be used to non-invasively identify tumor-specific mutations.

Feng Zhang, PhD (Damon Runyon-Rachleff Innovator ‘12-‘14) of the Broad Institute, Cambridge, and Jennifer A. Doudna, PhD (Damon Runyon Fellowship Sponsor, Former Fellowship Award Committee Member) of the University of California, Berkeley, were announced as recipients of the prestigious Canada Gairdner International Award for 2016 "for development of CRISPR-CAS as a genome editing tool for eukaryotic cells.” They are among five scientists honored for pioneering accomplishments in this field. 

Adam de la Zerda, PhD (Damon Runyon-Dale F. Frey Scientist ‘13, Damon Runyon Fellow ‘11-‘12) of Stanford University, Stanford, and colleagues, reported the success of a new technique called MOZART that enables 3D real-time imaging of individual cells or even molecules in a living animal. They were able to provide the first glimpse under the skin of a living animal, showing intricate details in the lymph and blood vessels.

Douglas K. Graham, MD, PhD (Damon Runyon Clinical Investigator ’07-’12), of Emory University School of Medicine, Atlanta, and colleagues, reported that a novel compound called MRX-2843 has shown promise in preclinical studies; it blocked the growth of acute myeloid leukemia (AML) cells, led to a significant level of cancer cell death and more than doubled the median days of survival in laboratory models with a drug-resistant form of the disease. MRX-2843 is effective at targeting cancer cells with activated MERTK protein.

Andrew T. Chan, MD, MPH (Damon Runyon Clinical Investigator ‘08-‘13) of Harvard Medical School and Massachusetts General Hospital, Boston, and colleagues, reported an analysis of data from two long-term epidemiologic studies showing that regular use of aspirin significantly reduces the overall risk of cancer. Their findings suggest that the use of aspirin may complement, but not replace, the preventive benefits of colonoscopy and other methods of cancer screening.